Brainsway ( (BWAY) ) has released its Q2 earnings. Here is a breakdown of the information Brainsway presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology. The company operates in the healthcare sector, focusing on improving mental health through innovative solutions.
In the second quarter of 2025, BrainsWay achieved record quarterly revenue of $12.6 million, marking a 26% increase compared to the same period in 2024. The company also reported an operating profit of $0.6 million and a significant rise in net profit to $2.0 million, reflecting a 233% increase year-over-year.
Key financial highlights include a gross margin of 75%, consistent with the previous year, and an adjusted EBITDA increase of 16% to $1.5 million. The company shipped 88 Deep TMS systems, expanding its installed base to 1,522 systems. BrainsWay’s strategic initiatives include equity financing with Stella MSO, LLC, and partnerships to enhance its market presence.
Looking ahead, BrainsWay has raised its full-year 2025 revenue guidance to between $50 million and $52 million, with expectations of operating income between 4% and 5% and adjusted EBITDA between 12% and 13%. The company remains focused on expanding its reach and enhancing its technology offerings to maintain its leadership in the mental health treatment space.